Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FINANCE ROUNDUP: Global Blood Doubles Post-IPO, GlobeImmune Considers Options, VC Deals Surge

This article was originally published in Scrip

Executive Summary

Global Blood Therapeutics launched an initial public offering at $20 per share and its stock price more than doubled to $43.11 at the end of its first day of trading on Aug. 12, proving that investors may be concerned about a biotechnology bubble, but they're not overly worried that it will burst soon.


Related Content

Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom
Finance Watch: Summer Slowdown Begins Ahead Of BIO, But Two IPOs Launched
venBio's $315m Pharma-Backed Fund Seeks Broad Range Of Investments


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts